Publications by authors named "Ian D Davis"

Claim this Profile
T
Target trial emulation of early docetaxel and enzalutamide for metastatic hormone-sensitive prostate cancer.
Yu Yang Soon, Ian C Marschner, I Manjula Schou, Christopher J Sweeney, Ian D Davis

BJU Int· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis.
Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, Kunwer Sufyan Faisal, Huan He, Kaneez Zahra Rubab Khakwani, Ian D Davis

Eur Urol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer.
Soumyajit Roy, Yilun Sun, Maha Hussain, Kim N Chi, Karim Fizazi, Ian D Davis

Nat Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What matters to society when making decisions about reimbursing drugs for prostate cancer: a discrete choice experiment.
Rafael Emilio De Feria Cardet, Stephen Goodall, Tracey-Lea Laba, Marion Haas, Ian D Davis

J Natl Cancer Inst· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumour-based epigenetic signatures as markers of prostate cancer aggressiveness after radical prostatectomy.
Yiyue Zhu, Elaheh Zarean, Danmeng L Li, Robert L O'Reilly, Ian D Davis

Br J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A roadmap for future clinical research in advanced prostate cancer: Findings from the Advanced Prostate Cancer Consensus Conference (APCCC) 2024.
Ursula M Vogl, Sara Merler, Antonio Angrisani, Fabio Turco, Ian D Davis

Eur J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
If the Treatment for Metastatic Hormone-sensitive Prostate Cancer Stops Working, What Next?
Ian D Davis

Eur Urol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Empowering people affected by penile cancer: towards a model for supportive self-management.
Catherine Paterson, Wayne Earle, David Homewood, Justin Chee, Henry Yao, Ian D Davis

Int J Impot Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial.
Louise Emmett, Nathan Papa, Shalini Subramaniam, Megan Crumbaker, Andrew Nguyen, Ian D Davis

Lancet Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial.
Edmond M Kwan, Sarah W S Ng, Sofie H Tolmeijer, Louise Emmett, Shahneen Sandhu, Ian D Davis

Nat Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Common inherited loss-of-function mutations in the innate sensor NOD2 contribute to exceptional immune response to cancer immunotherapy.
Megan B Barnet, Katherine J L Jackson, Etienne Masle-Farquhar, Amanda Russell, Deborah L Burnett, Ian D Davis

Proc Natl Acad Sci U S A· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How to Support Participants in Urogenital and Prostate Clinical Trials: A Qualitative Perspective.
Natasha A Roberts, Ian D Davis, David Wyld, Jeffrey Goh, Maxwell Thompson

Psychooncology· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer.
Matthew D Galsky, Mark Kockx, Juliette Roels, Roos Van Elzen, Xiangnan Guan, Ian D Davis

Cancer Immunol Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer.
Arun A Azad, Louise Kostos, Neeraj Agarwal, Gerhardt Attard, Ian D Davis

Eur Urol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
â
…But Words Will Never Hurt Me.
Ian D Davis, Angelyn Anton, Edmond M Kwan

Eur Urol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304).
Ciara Conduit, Andrisha-Jade Inderjeeth, Raymond Allen, Andrew J Martin, Wendy Parulekar, Ian D Davis

Future Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival and quality of life with [Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial.
Louise Emmett, Shalini Subramaniam, Megan Crumbaker, Anthony M Joshua, Shahneen Sandhu, Ian D Davis

Lancet Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC).
Silke Gillessen, Fabio Turco, Ian D Davis, Jason A Efstathiou, Karim Fizazi

Eur Urol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide in metastatic hormone-sensitive prostate cancer: A plain language summary of the ARCHES and ENZAMET follow-up studies.
Andrew J Armstrong, Arun A Azad, Ciara Conduit, Gabriel P Haas, Christopher Bland, Ian D Davis

Future Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and report.
Angela Meade, Elena Frangou, Babak Choodari-Oskooei, James Larkin, Tom Powles, Ian D Davis

Contemp Clin Trials Commun· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Systematic Review of the Use of Surgical Checklists in Transurethral Resection of Bladder Tumour.
Abram Botros, Paul M Rival, Ian D Davis, Shomik Sengupta

Cancers (Basel)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges of estimating treatment effects after a positive interim analysis.
Yu Yang Soon, Ian C Marschner, Manjula Schou, Christopher J Sweeney, Ian D Davis

Eur J Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of an Estrogen Receptor α-Selective F-Estradiol PET Tracer.
Pavel Sluka, Uwe Ackermann, Angela Rigopoulos, Hady Wardan, Carmel Pezaro, Ian D Davis

World J Nucl Med· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance.
Nima Sharifi, Robert Diaz, Hui-Ming Lin, Evan Roberts, Lisa G Horvath, Ian D Davis

J Clin Invest· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate Cancer.
Yu Yang Soon, Ian C Marschner, Manjula Schou, Michael S Hofman, Louise Emmett, Ian D Davis

JAMA Netw Open· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis